Target Price | $459.00 |
Price | $454.41 |
Potential |
1.01%
register free of charge
|
Number of Estimates | 31 |
31 Analysts have issued a price target Alnylam Pharmaceuticals, Inc 2026 .
The average Alnylam Pharmaceuticals, Inc target price is $459.00.
This is
1.01%
register free of charge
$598.50
31.71%
register free of charge
$230.79
49.21%
register free of charge
|
|
A rating was issued by 39 analysts: 31 Analysts recommend Alnylam Pharmaceuticals, Inc to buy, 8 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Alnylam Pharmaceuticals, Inc stock has an average upside potential 2026 of
1.01%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 2.25 | 3.57 |
22.97% | 58.79% | |
EBITDA Margin | -5.35% | 6.27% |
57.15% | 217.27% | |
Net Margin | -12.37% | 3.20% |
48.62% | 125.86% |
34 Analysts have issued a sales forecast Alnylam Pharmaceuticals, Inc 2025 . The average Alnylam Pharmaceuticals, Inc sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Alnylam Pharmaceuticals, Inc EBITDA forecast 2025. The average Alnylam Pharmaceuticals, Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
35 Alnylam Pharmaceuticals, Inc Analysts have issued a net profit forecast 2025. The average Alnylam Pharmaceuticals, Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.18 | 0.87 |
38.07% | 139.91% | |
P/E | 521.19 | |
EV/Sales | 16.17 |
35 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast for earnings per share. The average Alnylam Pharmaceuticals, Inc EPS is
This results in the following potential growth metrics and future valuations:
Alnylam Pharmaceuticals, Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
RBC Capital |
Locked
➜
Locked
|
Locked | Sep 19 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 16 2025 |
Evercore ISI Group |
Locked
➜
Locked
|
Locked | Sep 11 2025 |
BMO Capital |
Locked
➜
Locked
|
Locked | Sep 08 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 02 2025 |
Analyst Rating | Date |
---|---|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 19 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Sep 17 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 16 2025 |
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Sep 11 2025 |
Locked
BMO Capital:
Locked
➜
Locked
|
Sep 08 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
Sep 02 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 02 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.